Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Authors : Aysun IŞIKLAR, Gül BAŞARAN, Ozde Melisa CELAYİR, Gülçin KAHRAMAN, Jameela SOMANJE, Semra Öykü ÇOLAK, Mustafa SERTESER, Nurdan TOZUN

Pages : 332-338

Doi:10.31067/acusaglik.1247538

View : 77 | Download : 70

Publication Date : 2023-07-10

Article Type : Research Paper

Abstract :Background: Our study aimed to measure effectiveness of Anti-S1 RBD insert ignore into journalissuearticles values(receptor binding domain); IgG Antibody levels against SARS insert ignore into journalissuearticles values(severe acute respiratory syndrome); Cov-2 in breast cancer patients and compare them with healthy participants. Methods: This prospective cross-sectional, single-center study was designed to evaluate Anti-S1 RBD IgG antibody levels following SARS-CoV-2 vaccination in 54 breast cancer patients and 56 healthy controls without cancer diagnosis. Results: Anti-S1 RBD IgG antibody test was positive in 79.6% insert ignore into journalissuearticles values(43/54); of breast cancer patients, in 92.9% insert ignore into journalissuearticles values(52/56); of participants in the control group insert ignore into journalissuearticles values(p=0.054); and, 63.3% in breast cancer patients who were on chemotherapy+/-molecularly targeted therapy following at least two doses of vaccinations. Hybrid vaccination insert ignore into journalissuearticles values(use of two different types of vaccines); and more than two doses of vaccinations were associated with higher antibody titers both in patient and control groups. Median time to vaccination was 123 days insert ignore into journalissuearticles values(8-427); in the entire group and was significantly associated with antibody titer. Among breast cancer patients, type and frequency of vaccination, age and use of cytotoxic therapies were significantly associated with the magnitude of antibody response to SARS-CoV-2 vaccination in our study. Conclusion: Breast cancer patients developed a lower antibody response to vaccination against COVID-19 in comparison to healthy subjects. Clinical and treatment related factors might help in tailoring future vaccination strategies for specific subsets of breast cancer patients.
Keywords : Breast cancers, COVID 19, Anti S1 RBD IgG Antibody, SARS Cov 2 vaccine